SCHEMBL2919933

SCHEMBL2919933

Cc1n[nH]c2cc(Nc3ncc4ccc(N)c(C)c4n3)ccc12

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
VRK1 Q99986 1/20 0.38
JAK2 O60674 1/20 0.36
JAK1 P23458 2/20 0.35
JAK3 P52333 2/20 0.35
SGK1 O00141 1/20 0.35
SYK P43405 3/20 0.34
CDC7 O00311 1/20 0.34
GRM4 Q14833 4/20 0.34
MAPK10 P53779 2/20 0.34
JUN P05412 1/20 0.34
CDK1 P06493 1/20 0.34
CDK4 P11802 1/20 0.34
CCNB1 P14635 1/20 0.34
CCND1 P24385 1/20 0.34
CCNE1 P24864 1/20 0.34
CDK2 P24941 1/20 0.34
PDGFRB P09619 2/20 0.33
PDGFRA P16234 2/20 0.33
TERT O14746 1/20 0.33
DOT1L Q8TEK3 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2919791 0.87 SYK (0.41) SYKCDC7GRM4MAPK10CDK1
SCHEMBL2922072 0.87 CDK4 (0.41) VRK1JAK1JAK3SYKCDC7
SCHEMBL2916874 0.85 CDK4 (0.43) JAK2JAK1JAK3MAPK10CDK1
SCHEMBL2910896 0.83 CDC7 (0.52) JAK3SYKCDC7CDK2PDGFRB
SCHEMBL2917842 0.82 JAK1 (0.40) JAK2JAK1JAK3SYKGRM4
SCHEMBL2922109 0.81 ALK (0.34) VRK1CDK2PDGFRBPDGFRA
SCHEMBL2920288 0.80 PDGFRB (0.37) SYKCDC7GRM4CDK1CDK4
SCHEMBL2919139 0.76 VRK1 (0.44) VRK1JAK2JAK1JAK3SGK1
SCHEMBL29430461 0.76 SCN9A (0.49) CDK1CDK4CDK2TERTDOT1L
SCHEMBL4488694 0.76 SCN9A (0.49) CDK1CDK4CDK2TERTDOT1L

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100311965-A1 2-AMINOQUINAZOLINE DERIVATIVE CARNA BIOSCIENCES INC. (JP) 2010-12-09 US disclosed
US-20100311965-A1 2-AMINOQUINAZOLINE DERIVATIVE CARNA BIOSCIENCES INC. (JP) 2010-12-09 US disclosed
US-20100311965-A1 2-AMINOQUINAZOLINE DERIVATIVE CARNA BIOSCIENCES INC. (JP) 2010-12-09 US disclosed
EP-2226315-A1 2-AMINOQUINAZOLINE DERIVATIVE Carna Biosciences Inc. (JP) 2010-09-08 EP disclosed
WO-2009084695-A1 2-AMINOQUINAZOLINE DERIVATIVE CARNA BIOSCIENCES INC. (JP) 2009-07-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100311965-A1 2-AMINOQUINAZOLINE DERIVATIVE DSTYK, ABL1, EEF2K VRK1 314/4885JAK2 216/4885JAK1 408/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.